Loading...Loading...Thursday, Novo Nordisk A/S NVO is holding its Capital Markets Day. Its executive management and other members of senior management will provide a full review of strategy, operations, and financial targets.During its early session, the company, at its investor event, said early trial data for its experimental obesity drug amycretin showed a higher weight loss than its Wegovy (semaglutide) treatment.Amycretin is an oral medicine that targets the same GLP-1 hormone as other highly popular weight loss drugs like Novo’ Nordisk’s Wegovy and Eli Lilly And Co’s LLY Zepbound (tirzepatide), which regulates hunger.In the Phase 1 trial, oral amycretin showed that participants lost 13.1% of their weight after 12 weeks.

正在加载。。。正在加载。。。星期四，诺和诺德公司将举行资本市场日。其执行管理层和其他高级管理层成员将对战略、运营和财务目标进行全面审查。在早期会议期间，该公司在其投资者活动上表示，其实验性肥胖药物amycretin的早期试验数据显示，其体重减轻程度高于其Wegovy（semaglutide）治疗。Amycretin是一种口服药物，其靶向与其他广受欢迎的减肥药物相同的GLP-1激素，如诺和诺德公司的Wegovy和礼来公司以及Co公司的LLY Zepbound（tirzepatide），它可以调节饥饿。在第一阶段试验中，口服胰淀素显示参与者在12周后体重减轻了13.1%。

That compares to a weight loss of 5.9% after 12 weeks in a trial for Wegovy.Wegovy showed an overall weight loss of 15% after two years of treatment vs. 2.6% (~6 lb) for adults taking a placebo.The Danish pharma giant said amycretin appeared to be safe and well-tolerated and had adverse effects in line with previous Novo Nordisk GLP-1 and CagriSema trials.Novo Nordisk will begin a Phase 2 trial of its experimental drug amycretin during later 2024, with results due in early 2026.In its presentation, the company said amycretin will be tested in a phase 2 trial with oral and subcutaneous administration in people with type 2 diabetes, with the trial expected to be initiated in the second half of 2024.A mid-stage study sponsored by the National Institutes of Health showed that the weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease.Novo Nordisk’s FLOW kidney outcomes trial demonstrated a statistically significant and superior reduction in kidney disease progression .

相比之下，在Wegovy的一项试验中，12周后体重减轻了5.9%。经过两年的治疗，Wegovy的总体体重减轻了15%，而服用安慰剂的成年人体重减轻了2.6%（约6磅）。这家丹麦制药巨头表示，amycretin似乎安全且耐受性良好，并且与之前的诺和诺德GLP-1和CagriSema试验一致，具有不良反应。诺和诺德将于2024年晚些时候开始其实验药物amycretin的第二阶段试验，结果将于2026年初公布。该公司在介绍中表示，amycretin将在2型糖尿病患者的口服和皮下给药的第二阶段试验中进行测试，预计该试验将于2024年下半年开始。美国国立卫生研究院（National Institutes of Health）赞助的一项中期研究表明，每周注射semaglutide已被证明是安全有效的，可减少HIV和脂肪肝患者的肝脏脂肪。诺和诺德的流动肾脏结果试验显示肾脏疾病进展的统计学显着和优越的减少。